ClinicalTrials.gg
CompletedNCT00817219Updated Mar 12, 2025Results posted

Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris

A Phase 2 interventional study of Calcipotriene plus betamethasone dipropionate ointment in Psoriasis Vulgaris, sponsored by LEO Pharma. Completed at 8 sites in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by LEO Pharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies testing calcipotriene in Psoriasis — 2 open to participants now, 2 under way, none of them phase 3. calcipotriene · Psoriasis.

Enrollment
35th of 47
33 · median 200
Started
2009
the only one that year
Phase 2
9 of 47
none open now
Registered
17th of 47
by date
Lead sponsor
22 of 47
LEO Pharma

Among the 47 studies testing calcipotriene in Psoriasis, this one is the 35th largest by enrollment, is the only one that started in 2009, is one of 9 in phase 2, and was the 17th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

2 of the 47 studies testing calcipotriene in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About calcipotriene

calcipotriene: first FDA approval 1993 (DOVONEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing calcipotriene in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of 4 weeks of TACLONEX ointment in adolescent patients with psoriasis vulgaris.

Read the detailed description

TACLONEX ointment has marketing approval in many countries for the treatment of psoriasis vulgaris in adults. No studies have been conducted in patients less than 18 years of age. However, about 25% of affected individuals are diagnosed between 10 and 19 years of age, hence psoriasis is also prevalent in the adolescent age group (12-17 years).

All patients will receive TACLONEX. To evaluate the safety of TACLONEX ointment, all adverse events will be recorded. In addition, any systemic absorption of the active components, betamethasone dipropionate and calcipotriene, will be evaluated by assessing adrenal function (using CORTROSYN™ test) and calcium metabolism (by measuring serum calcium and the urinary calcium:creatinine ratio), respectively.

03

Conditions studied

  • Psoriasis Vulgaris

Browse trials for

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 12 to 17 years, inclusive.
  • Psoriasis vulgaris on the trunk and/or limbs which is:
  • amenable to topical treatment
  • of an extent of 5-30% of BSA
  • of at least a moderate severity
  • A serum cortisol concentration above 5 mcg/dL before ACTH-challenge and above 18 mcg/dL at 30 minutes after ACTH-challenge.
  • Albumin-corrected serum calcium and urinary calcium:creatinine ratio within the reference range.

Exclusion criteria

Exclusion Criteria:

  • Serious allergy, serious asthma, or serious allergic skin rash.
  • A history of sensitivity to any medication.
  • PUVA or Grenz ray therapy, UVB therapy, systemic treatment with biological therapies, , or other therapies with an effect on psoriasis, topical treatment with corticosteroids or vitamin D analogues, treatment with enzymatic inductors, cytochrome P450 inhibitors, hypoglycemic sulfonamides, antidepressive medications, estrogen therapy, calcium supplements or vitamin D supplements.
  • Guttate, erythrodermic, exfoliative or pustular psoriasis.
  • Viral lesions of the skin, fungal or bacterial skin infections, ulcers or wounds.
  • Severe renal insufficiency, severe hepatic disorders, disorders of calcium metabolism associated with hypercalcemia, any cardiac condition or endocrine disorder.
  • Diabetes mellitus
  • Cushing's disease or Addison's disease.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    TACLONEX ointment

    Drug: Calcipotriene plus betamethasone dipropionate ointment

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse Drug Reactions

    The number of participants experiencing each type of adverse drug reaction. Adverse drug reactions were defined as adverse events for which the investigator had not described the causal relationship to trial medication as "not related".

    Time frame: Week 4

  2. Serum Cortisol Concentration of ≤18 mcg/dL at 30 Minutes After ACTH-challenge at End of Treatment

    The ACTH(Adrenocorticotropic hormone)-challenge test involves injecting a synthetic subunit of ACTH into the patient,and measuring the cortisol produced by the adrenal glands 30 and 60 minutes after the injection.

    Time frame: Week 4

  3. Serum Cortisol Concentration of ≤18 mcg/dL at 30 and 60 Minutes After ACTH-challenge at End of Treatment

    The ACTH(Adrenocorticotropic hormone)-challenge test involves injecting a synthetic subunit of ACTH into the patient,and measuring the cortisol produced by the adrenal glands 30 and 60 minutes after the injection.

    Time frame: Week 4

  4. Change in Albumin Corrected Serum Calcium From Baseline to End of Treatment

    Time frame: Baseline and 4 weeks

  5. Change in Urinary Calcium:Creatinine Ratio From Baseline to End of Treatment.

    Time frame: Baseline and 4 Weeks

Secondary outcomes

  1. "Controlled Disease"(i.e., "Clear" or "Almost Clear") According to the Investigator's Global Assessment of Disease Severity at Week 4.

    The investigator made an assessment of the disease severity (Plaque thickening, Scaling and Erythema) using a 6-point scale (Clear, Almost clear, Mild, Moderate, Severe, and Very severe). This assessment represented the average lesion severity on the trunk and limbs.

    Time frame: Week 4

  2. "Controlled Disease"(i.e., "Clear" or "Very Mild") According to the Patient's Global Assessment of Disease Severity at Week 4.

    The patient made an assessment of the disease severity using a 5-point scale (Clear, Very Mild, Mild, Moderate, and Severe).

    Time frame: Week 4

  3. Percentage Change in PASI From Baseline to Week 4.

    PASI is Psoriasis Area and Severity Index and is based on the investigator's assessment of extent and severity of the disease. It can range from 0 (best) to 64.8(worst). The PASI used in this trial is modified to exclude assessment of the head, as trial treatment is not used here.

    Time frame: Baseline and 4 weeks

  4. PASI 75 at Week 4.

    PASI 75 is at least 75% reduction in PASI from baseline. PASI is Psoriasis Area and Severity Index and is based on the investigator's assessment of extent and severity of the disease. It can range from 0 (best) to 64.8(worst). The PASI used in this trial is modified to exclude assessment of the head, as trial treatment is not used here.

    Time frame: 4 weeks

  5. PASI 50 at Week 4.

    PASI 50 is at least 50% reduction in PASI from baseline. PASI is Psoriasis Area and Severity Index and is based on the investigator'sassessment of extent and severity of the disease. It can range from 0 (best) to 64.8(worst). The PASI used in this trial is modified to exclude assessment of the head, as trial treatment is not used here.

    Time frame: Week 4

07

Results

Posted Jan 7, 2013

Participant flow

The study period was 15 July 2009 (date of first subject's first screening visit) to 05 December 2011 (date of the last subject's last on-treatment visit)

Participant flow — Overall Study
MilestoneTACLONEX Ointment
Started33
Completed33
Not completed0

Outcome measures

PrimaryAdverse Drug Reactions

The number of participants experiencing each type of adverse drug reaction. Adverse drug reactions were defined as adverse events for which the investigator had not described the causal relationship to trial medication as "not related".

Time frame:
Week 4
Reported as:
Number · participants
Adverse Drug Reactions
participantsTACLONEX Ointment
Adverse Drug Reactions2
PrimarySerum Cortisol Concentration of ≤18 mcg/dL at 30 Minutes After ACTH-challenge at End of Treatment

The ACTH(Adrenocorticotropic hormone)-challenge test involves injecting a synthetic subunit of ACTH into the patient,and measuring the cortisol produced by the adrenal glands 30 and 60 minutes after the injection.

Time frame:
Week 4
Reported as:
Number · participants
Serum Cortisol Concentration of ≤18 mcg/dL at 30 Minutes After ACTH-challenge at End of Treatment
participantsTACLONEX Ointment
Serum Cortisol Concentration of ≤18 mcg/dL at 30 Minutes After ACTH-challenge at End of Treatment0
PrimarySerum Cortisol Concentration of ≤18 mcg/dL at 30 and 60 Minutes After ACTH-challenge at End of Treatment

The ACTH(Adrenocorticotropic hormone)-challenge test involves injecting a synthetic subunit of ACTH into the patient,and measuring the cortisol produced by the adrenal glands 30 and 60 minutes after the injection.

Time frame:
Week 4
Reported as:
Number · participants
Serum Cortisol Concentration of ≤18 mcg/dL at 30 and 60 Minutes After ACTH-challenge at End of Treatment
participantsTACLONEX Ointment
Serum Cortisol Concentration of ≤18 mcg/dL at 30 and 60 Minutes After ACTH-challenge at End of Treatment0
PrimaryChange in Albumin Corrected Serum Calcium From Baseline to End of Treatment
Time frame:
Baseline and 4 weeks
Reported as:
Mean · mmol/L
Change in Albumin Corrected Serum Calcium From Baseline to End of Treatment
mmol/LTACLONEX Ointment
Change in Albumin Corrected Serum Calcium From Baseline to End of Treatment0.005 ± 0.094
PrimaryChange in Urinary Calcium:Creatinine Ratio From Baseline to End of Treatment.
Time frame:
Baseline and 4 Weeks
Reported as:
Mean · mmol/g
Change in Urinary Calcium:Creatinine Ratio From Baseline to End of Treatment.
mmol/gTACLONEX Ointment
Change in Urinary Calcium:Creatinine Ratio From Baseline to End of Treatment.0.717 ± 2.877
Secondary"Controlled Disease"(i.e., "Clear" or "Almost Clear") According to the Investigator's Global Assessment of Disease Severity at Week 4.

The investigator made an assessment of the disease severity (Plaque thickening, Scaling and Erythema) using a 6-point scale (Clear, Almost clear, Mild, Moderate, Severe, and Very severe). This assessment represented the average lesion severity on the trunk and limbs.

Time frame:
Week 4
Reported as:
Number · participants
"Controlled Disease"(i.e., "Clear" or "Almost Clear") According to the Investigator's Global Assessment of Disease Severity at Week 4.
participantsTACLONEX Ointment
"Controlled Disease"(i.e., "Clear" or "Almost Clear") According to the Investigator's Global Assessment of Disease Severity at Week 4.20
Secondary"Controlled Disease"(i.e., "Clear" or "Very Mild") According to the Patient's Global Assessment of Disease Severity at Week 4.

The patient made an assessment of the disease severity using a 5-point scale (Clear, Very Mild, Mild, Moderate, and Severe).

Time frame:
Week 4
Reported as:
Number · participants
"Controlled Disease"(i.e., "Clear" or "Very Mild") According to the Patient's Global Assessment of Disease Severity at Week 4.
participantsTACLONEX Ointment
"Controlled Disease"(i.e., "Clear" or "Very Mild") According to the Patient's Global Assessment of Disease Severity at Week 4.23
SecondaryPercentage Change in PASI From Baseline to Week 4.

PASI is Psoriasis Area and Severity Index and is based on the investigator's assessment of extent and severity of the disease. It can range from 0 (best) to 64.8(worst). The PASI used in this trial is modified to exclude assessment of the head, as trial treatment is not used here.

Time frame:
Baseline and 4 weeks
Reported as:
Mean · percentage
Percentage Change in PASI From Baseline to Week 4.
percentageTACLONEX Ointment
Percentage Change in PASI From Baseline to Week 4.-72.5 (-81.1 to -63.9)
SecondaryPASI 75 at Week 4.

PASI 75 is at least 75% reduction in PASI from baseline. PASI is Psoriasis Area and Severity Index and is based on the investigator's assessment of extent and severity of the disease. It can range from 0 (best) to 64.8(worst). The PASI used in this trial is modified to exclude assessment of the head, as trial treatment is not used here.

Time frame:
4 weeks
Reported as:
Number · participants
PASI 75 at Week 4.
participantsTACLONEX Ointment
PASI 75 at Week 4.17
SecondaryPASI 50 at Week 4.

PASI 50 is at least 50% reduction in PASI from baseline. PASI is Psoriasis Area and Severity Index and is based on the investigator'sassessment of extent and severity of the disease. It can range from 0 (best) to 64.8(worst). The PASI used in this trial is modified to exclude assessment of the head, as trial treatment is not used here.

Time frame:
Week 4
Reported as:
Number · participants
PASI 50 at Week 4.
participantsTACLONEX Ointment
PASI 50 at Week 4.28

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TACLONEX Ointment—0/33 (0%)10/33 (30.3%)
Most frequent other events
Most frequent other events
EventTACLONEX Ointment
Upper respiratory tractInfections and infestations2/33
HeadacheNervous system disorders2/33
Tension headacheNervous system disorders2/33
CoughRespiratory, thoracic and mediastinal disorders2/33
Rash papularSkin and subcutaneous tissue disorders2/33

Baseline characteristics

Age, Continuous
Age, Continuous(years)TACLONEX Ointment
Mean14.6 ± 1.6
Sex: Female, Male
Sex: Female, Male(Participants)TACLONEX Ointment
Female17
Male16
08

Study locations

8 sites
  • Center for Dermatology Clinical Research
    Fremont, California 94538, United States
  • University of California at San Diego/Rady Children's Hospital
    San Diego, California 92123, United States
  • Ameriderm Research
    Maitland, Florida 32751, United States
  • Northwestern University's Feinberg School of Medicine
    Chicago, Illinois 60611-2997, United States
  • Arlington Research Center
    Arlington, Texas 76011, United States
  • University of Texas-Dermatology
    Houston, Texas 77030, United States
  • Virginia Clinical Research, Inc.
    Norfolk, Virginia 23507, United States
  • DBA Dermatology Associates
    Seattle, Washington 98101, United States
09

References and documents

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2013, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2009
First posted
Jan 6, 2009
Start
Jul 2009
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Results first posted
Jan 7, 2013
Last update
Mar 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00817219
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Jan 6, 2009
Start date
Jul 2009
Primary completion
Dec 2011
Completion
Dec 2011
Results posted
Jan 7, 2013
Last update
Mar 12, 2025

Study contacts

Amy S Paller, MD
principal investigator · Northwestern University's Feinberg School of Medicine

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Calcipotriene · Betamethasone dipropionate

Start the discussion